Today: 1 May 2026
Browse Category

ASX:CGS 10 December 2025

ASX Biggest Losers Today: Cogstate, Immuron and GQG Partners Lead Australian Stock Market Declines (10 December 2025)

ASX Biggest Losers Today: Cogstate, Immuron and GQG Partners Lead Australian Stock Market Declines (10 December 2025)

Cogstate shares fell over 16% to $2.10 after the company cut profit and revenue guidance, triggering heavy selling. The S&P/ASX 200 hovered near flat by mid-session, masking sharp losses in healthcare, speculative miners, and financials. Immuron plunged 37%, Tusker Minerals dropped 27%, and Janus Electric slid 24%. The 10-year Australian bond yield rose above 4.8%, pressuring growth stocks.
10 December 2025
·····

Stock Market Today

  • Investors Eye FTSE 250's Applied Nutrition as Diageo Shares Falter
    May 1, 2026, 11:39 AM EDT. Diageo shares have slumped about 30% over the past year and more than 50% in five years, pressuring investors. Applied Nutrition, a FTSE 250 nutritional supplement supplier, offers a contrasting growth story with a 57% rise in sales over six months and a near 90% rise in share price over one year. The company benefits from booming health and wellness trends, expects 8% market growth annually through 2028, and features strong financials including a £25.4 million net cash position, 49% return on capital, and a modest forward price-to-earnings ratio of 17.5. Its business-to-business model with retailers like Tesco and Amazon helps navigate industry competition. Investors seeking to recover losses from Diageo may consider Applied Nutrition's robust outlook and expanding market.

Latest article

Tempus AI’s Big May: Why Q1 Results and First Investor Day Put TEM Stock in Focus

Tempus AI’s Big May: Why Q1 Results and First Investor Day Put TEM Stock in Focus

1 May 2026
CHICAGO, May 1, 2026, 10:03 CDT Tempus AI Inc will hold its first investor day on May 29, giving Wall Street a new date to test the company’s pitch that it can grow beyond genetic testing into a larger healthcare data and artificial intelligence business. The event comes three and a half weeks after Tempus reports first-quarter results on May 5. (Tempus AI) The timing matters. Investors are trying to judge whether Tempus is mainly a fast-growing diagnostics company or a data platform that can keep signing drugmakers to long-term work in oncology, where precision medicine means using genetic and
Ciena Corporation Stock Faces $416 Reality Check as AI Network Push Heads to Brazil

Ciena Corporation Stock Faces $416 Reality Check as AI Network Push Heads to Brazil

1 May 2026
Rothschild & Co Redburn initiated Ciena with a Neutral rating and a $416 target, about 22% below Friday’s $534.43 share price, citing that much of the optical-networking upside is already priced in. Ciena reported Q1 revenue of $1.43 billion, up 33%, and raised its 2026 forecast. The company will showcase new optical products at ABRINT 2026 in São Paulo next week.
Go toTop